Bladder Cancer Clinical Trials in Changsha, Hunan
7 recruitingChangsha, Hunan, China
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled15 locationsNCT07283835
Recruiting
Phase 1Phase 2
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Suzhou Forlong Biotechnology Co., Ltd80 enrolled12 locationsNCT07122414
Recruiting
Phase 1Phase 2
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University36 enrolled8 locationsNCT06364956
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.152 enrolled14 locationsNCT06186414
Recruiting
Phase 1Phase 2
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Bladder CancerNon Muscle Invasive
Zhuhai Beihai Biotech Co., Ltd48 enrolled6 locationsNCT06732531
Recruiting
Phase 1Phase 2
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.24 enrolled6 locationsNCT06378242